1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,565 | 0,615 | 02.02. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| INTEGRAGEN Aktie jetzt für 0€ handeln | |||||
| 15.01. | IntegraGen reports revenue drop, eyes growth in genomics | 2 | Investing.com | ||
| 15.01. | IntegraGen meldet Umsatzrückgang, setzt auf Wachstum in der Genomik | 1 | Investing.com Deutsch | ||
| 15.01. | IntegraGen: 2024 Revenues of €8.5m, Down 27% Compared With 2023 (+5% Excluding SeqOIA), and Cash Position of €1.9m | 259 | Business Wire | Revenues down 27% due to the discontinuation of services for the SeqOIA platform. Adjusted for this base effect, growth stood at 5% over the period.
- Cash position of 1,895 k€ at December 31, 2024.... ► Artikel lesen | |
| 17.10.24 | IntegraGen: 2024 Half-Year Results - Sales up 6% on a Like-for-Like Basis (Excluding SeqOIA) and Profitability Maintained | 249 | Business Wire | Revenue growth for the Évry laboratory activities Restructuring and cost reduction plan implemented after cessation of services to SeqOIA in February Overall profitability remained... ► Artikel lesen | |
| 18.07.24 | IntegraGen: First-Half 2024 Sales of €4.5m, up 6% on the Scope Excluding SeqOIA and Cash Position of €2.8m | 351 | Business Wire | The discontinuation of services for the SeqOIA platform mechanically led to a 20% reduction in revenues in the first half of the year. Adjusted for this base effect, growth was 6% over the period.... ► Artikel lesen | |
| 18.04.24 | IntegraGen: Annual Results 2023 - Positive EBITDA Reflecting Tight Cost Control | 379 | Business Wire | EVRY, France--(BUSINESS WIRE)--Regulatory News:
IntegraGen (FR0010908723 - ALINT - Eligible PEA PME), an OncoDNA company specializing in the genomics of cancer and rare genetic diseases, which... ► Artikel lesen |
6 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 57,50 | +0,54 % | Tempus AI (NASDAQ:TEM) Stock Price Up 6.3% - Should You Buy? | ||
| QIAGEN | 42,895 | -0,01 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 28.01.2025 | Das Instrument O92 CA98956B1031 ZEUS NORTH AMER.MINING C. EQUITY wird cum Kapitalmassnahme gehandelt am 28.01.2025 und ex Kapitalmassnahme am 29.01.2025 The instrument O92 CA98956B1031 ZEUS NORTH AMER.MINING... ► Artikel lesen | |
| IMMUNOVANT | 21,740 | -1,50 % | Here's Why Immunovant, Inc. (IMVT) Will Double in 2025 | ||
| RECURSION PHARMACEUTICALS | 7,240 | -5,85 % | How Is The Market Feeling About Recursion Pharmaceuticals? | ||
| IMMUNOME | 11,030 | +4,95 % | Immunome Inc. - 8-K, Current Report | ||
| MAZE THERAPEUTICS | 15,950 | 0,00 % | Maze Therapeutics Prices Upsized IPO Of 8.75 Mln Shares At $16.00/shr | WASHINGTON (dpa-AFX) - Maze Therapeutics Inc. (MAZE) announced that it has priced its upsized initial public
offering of 8.75 million shares of its common stock at a public offering price... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 37,500 | +0,73 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 20, 2025 | ||
| AVIDITY BIOSCIENCES | 32,930 | +0,92 % | Avidity Biosciences, Inc.: Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025 | Accelerated approval path confirmed for del-zota; Biologics License Application (BLA) submission planned for year end 2025
On track to complete enrollment in del-desiran... ► Artikel lesen | |
| EVOTEC | 8,650 | +0,82 % | BioTech - jetzt geht's los! 100 % Chancen für Evotec, BioNxt, Bayer, Formycon und Novo Nordisk! | Der DAX 40-Index erreichte in der letzten Woche mit 21.520 Punkten ein neues Allzeithoch. Das klingt auf den ersten Blick komisch, denn die Hälfte aller Werte krebst an mehrjährigen Tiefstständen. Zugpferde... ► Artikel lesen | |
| JANUX THERAPEUTICS | 43,480 | -2,92 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 53,76 | +3,90 % | A Glimpse Into The Expert Outlook On Tarsus Pharmaceuticals Through 4 Analysts | ||
| ARS PHARMACEUTICALS | 13,020 | -8,89 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates | Commercial launch of neffy® (epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025Exclusive... ► Artikel lesen | |
| 89BIO | 9,600 | -0,52 % | 89bio, Inc. - 8-K, Current Report | ||
| DYNE THERAPEUTICS | 14,220 | +0,57 % | Dyne Therapeutics (NASDAQ:DYN) Sees Large Volume Increase - What's Next? | ||
| BIONTECH | 118,90 | -0,34 % | JPMORGAN stuft Biontech auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat das Kursziel für Biontech von 122 auf 120 US-Dollar gesenkt und die Einstufung auf "Neutral" belassen. Ihre aktualisierten Schätzungen für die... ► Artikel lesen |
Das Unternehmen INTEGRAGEN kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,535 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INTEGRAGEN finden Sie auf Wallstreet Online.
